Wire · opportunities
Roche's Genentech inks $1.5B bispecific pact with fast-rising Earendil
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 25 September 2026 · Fusion42 review
Roche's Genentech has signed a $1.5 billion+ deal with Earendil Labs to develop multiple bispecific antibodies for oncology. Genentech will manage global clinical development and commercialisation, while Earendil leads antibody discovery using its AI-driven platform.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Oncology drug founders need to engage with AI-driven antibody discovery platforms like Earendil now as big pharma is redirecting pipeline assets to startups. Earendil’s model shows clinical-stage partnerships pay off; stake your claim before competitors do.
◆ Coverage
1 source · 25 Sep 2026
◆ Related on Wire
◆ Topics